PT - JOURNAL ARTICLE AU - Yukinori Harada AU - Shintaro Kakimoto AU - Taro Shimizu TI - Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma AID - 10.1136/bcr-2020-235177 DP - 2020 Jul 01 TA - BMJ Case Reports PG - e235177 VI - 13 IP - 7 4099 - http://casereports.bmj.com/content/13/7/e235177.short 4100 - http://casereports.bmj.com/content/13/7/e235177.full SO - BMJ Case Reports2020 Jul 01; 13 AB - Pazopanib is a multi-targeted tyrosine kinase inhibitor, which is indicated for use in patients with advanced renal cell carcinoma or advanced soft-tissue sarcomas. Although rare, interstitial lung disease has been reported as among the adverse sequelae of pazopanib therapy. We report the case of a 75-year-old man who developed interstitial lung disease during treatment with pazopanib for renal cell carcinoma with multiple lung metastases. The patient presented with dry cough and new-onset fatigue 3 months after initiation of pazopanib. He had mild hypoxia with bilateral ground-glass opacities on chest CT. He was treated with antibiotics for presumptive pneumonia, but his respiratory status rapidly deteriorated, and he required non-invasive positive pressure ventilation. He recovered on discontinuation of pazopanib and systemic steroids. Clinicians should recognise that interstitial lung disease can occur in patients who are undergoing treatment with pazopanib.